Twice daily) among HIV/TB co-infected adults taking RMP-containing TB treatment with focus on HIV viral suppression and hepatotoxicity (ii) Evaluation of super-boosted LPV (1 : 1 LPV/r ratio with weight-based dosing) among HIV/TB co-infected children receiving RMP-containing TB treatment with focus on LPV PK and HIV viral suppression (iii) Evaluation of EFV at 600 mg versus 800 mg daily among pati